Baxter International, Inc. Receives Marketing Authorization in European Union for VEPACEL Pre-Pandemic Influenza Vaccine

Published: Mar 02, 2012

VIENNA--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) announced today that the European Commission (EC) has granted marketing authorization for VEPACEL in all European Union (EU) Member States, as well as Iceland, Liechtenstein and Norway.

Back to news